Hetacillin
WikiDoc Resources for Hetacillin |
Articles |
---|
Most recent articles on Hetacillin |
Media |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on Hetacillin at Clinical Trials.gov Clinical Trials on Hetacillin at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on Hetacillin
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Patient resources on Hetacillin Discussion groups on Hetacillin Patient Handouts on Hetacillin Directions to Hospitals Treating Hetacillin Risk calculators and risk factors for Hetacillin
|
Healthcare Provider Resources |
Causes & Risk Factors for Hetacillin |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
Hetacillin is a beta-lactam. Hetacillin is a prodrug and it has no intrinsic antibacterial activity, but is converted by the body to ampicillin, which is active against a variety of organisms.
Administration
Hetacillin is administered orally. The potassium salt, hetacillin potassium, is administered by injection, either intravenously or intramuscularly.
Hetacillin was removed from the market for human use when the discovery was made that it is actually cleaved in the GI tract to formaldehyde and had no benefit to non-ester derivatives (i.e. Ampicillin). Template:SIB